Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Classical hematology 1

Conditions

Anemia 116Neoplasms 77Anemia, Refractory, with Excess of Blasts 32Myelodysplastic Syndromes 31Leukemia, Myeloid, Acute 28Venous Thromboembolism 25Thrombocytopenia 24Leukemia 22Breast Neoplasms 22Febrile Neutropenia 21Neutropenia 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Multiple Myeloma 15Lymphoma 14Hematologic Neoplasms 14Anemia, Sickle Cell 14Ovarian Neoplasms 12Myeloproliferative Disorders 10Leukemia, Lymphocytic, Chronic, B-Cell 10Fanconi Anemia, Complementation Group D1 10Venous Thrombosis 9Primary Myelofibrosis 9Lung Neoplasms 9Leukemia, Myelomonocytic, Chronic 9Prostatic Neoplasms 8Lymphoma, Non-Hodgkin 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Hodgkin Disease 8Pulmonary Embolism 7Hemophilia A 7

Interventions

Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Agnosia × Classical hematology × Clear all
NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡